We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Emergent Biosolutions Inc | NYSE:EBS | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.2399 | 6.17% | 4.1299 | 4.51 | 3.84 | 3.88 | 7,704,319 | 18:51:46 |
From May 2023 to May 2024
By Dean Seal
A wing of the U.S. Department of Health and Human Services has awarded Emergent BioSolutions a 10-year contract worth up to $704 million for the development and production of an Ebola virus treatment.
The Gaithersburg, Md.-based biotechnology company Monday that the contract comes from the Biomedical Advanced Research and Development Authority, which is part of the department's Administration for Strategic Preparedness and Response.
The contract calls for the advanced development, manufacturing scale-up and procurement of Ebanga, a licensed treatment for Ebola virus disease.
Shares rose 7.7% to $7.41 in after-market trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 31, 2023 16:49 ET (20:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Emergent Biosolutions Chart |
1 Month Emergent Biosolutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
